Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

DIABEO App Software and Telemedicine Versus Usual Follow-Up in the Treatment of Diabetic Patients: Protocol for the TELESAGE Randomized Controlled Trial.

Jeandidier N, Chaillous L, Franc S, Benhamou PY, Schaepelynck P, Hanaire H, Catargi B, Farret A, Fontaine P, Guerci B, Reznik Y, Penfornis A, Borot S, Serusclat P, Kherbachi Y, D'Orsay G, Detournay B, Simon P, Charpentier G.

JMIR Res Protoc. 2018 Apr 19;7(4):e66. doi: 10.2196/resprot.9154.

2.

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis.

Charbonnel B, Simon D, Dallongeville J, Bureau I, Dejager S, Levy-Bachelot L, Gourmelen J, Detournay B.

Pharmacoecon Open. 2018 Jun;2(2):209-219. doi: 10.1007/s41669-017-0050-3.

3.

Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.

Andrade LF, Saba G, Ricard JD, Messika J, Gaillat J, Bonnin P, Chidiac C, Illes HG, Laurichesse H, Detournay B, Petitpretz P, de Pouvourville G.

Health Qual Life Outcomes. 2018 Feb 2;16(1):28. doi: 10.1186/s12955-018-0854-6.

4.

The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study.

Balkau B, Charbonnel B, Penfornis A, Chraibi N, Lahouegue A, Faure C, Thomas-Delecourt F, Detournay B.

Diabetes Ther. 2017 Oct;8(5):1147-1162. doi: 10.1007/s13300-017-0311-2. Epub 2017 Sep 25.

5.

[Self-monitoring of blood glucose in France: data from a national survey].

Guerci B, Benhamou PY, Durain D, Bahloul A, Jeanbat V, Detournay B.

Sante Publique. 2017 Apr 27;29(2):229-240. French.

PMID:
28737342
6.

Costs associated with community acquired pneumonia in France.

Saba G, Andrade LF, Gaillat J, Bonnin P, Chidiac C, Illes HG, Laurichesse H, Messika J, Ricard JD, Detournay B, Petitpretz P, de Pouvourville G.

Eur J Health Econ. 2018 May;19(4):533-544. doi: 10.1007/s10198-017-0900-z. Epub 2017 May 25.

PMID:
28547724
7.

Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes.

Moutairou A, Roussel R, Charbonnel B, Leye A, Detournay B, Mohammedi K, Potier L.

Diabetes Metab. 2017 Sep;43(4):392-394. doi: 10.1016/j.diabet.2016.11.009. Epub 2017 Feb 1. No abstract available.

PMID:
28161368
8.

[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization].

Hanaire H, Attali C, Lecointre B, Fraysse M, Gouet D, Babel MR, Charbonnel B, Sarkozy F, Gourmelen J, Detournay B.

Sante Publique. 2016 Dec 19;28(6):781-789. French.

PMID:
28155773
9.

[Economic consequences of biological monitoring and medical complications of injectable anticoagulants in France].

Paubel P, Cousin M, Amar C, Gourmelen J, Fabron C, Detournay B.

J Mal Vasc. 2016 Dec;41(6):371-377. doi: 10.1016/j.jmv.2016.10.001. Epub 2016 Nov 4. French.

PMID:
27817998
10.

Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial.

Moutairou A, Roussel R, Charbonnel B, El Boustany R, Nicolas A, Leye A, Mohammedi K, Marre M, Detournay B, Potier L.

Diabetes Metab. 2017 Apr;43(2):187-190. doi: 10.1016/j.diabet.2016.08.001. Epub 2016 Sep 21. No abstract available.

PMID:
27665052
11.

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.

Conget I, Mauricio D, Ortega R, Detournay B; CHADIG Study investigators.

BMJ Open. 2016 Jul 26;6(7):e010197. doi: 10.1136/bmjopen-2015-010197. Erratum in: BMJ Open. 2017 Feb 13;7(2):e010197corr1.

12.

Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study.

Roussel R, Charbonnel B, Behar M, Gourmelen J, Emery C, Detournay B.

Diabetes Ther. 2016 Sep;7(3):537-49. doi: 10.1007/s13300-016-0185-8. Epub 2016 Jul 15.

13.

Cost of Type 2 Diabetes According to Glucose-Lowering Medications in France.

Charbonnel B, Dallongeville J, Simon D, Bureau I, Leproust S, Levy-Bachelot L, Gourmelen J, Detournay B.

Value Health. 2015 Nov;18(7):A604. doi: 10.1016/j.jval.2015.09.2079. Epub 2015 Oct 20. No abstract available.

14.

Patterns of Pharmacological Treatment in Type 2 Diabetes in France in 2013.

Simon D, Dallongeville J, Charbonnel B, Bureau I, Detournay B, Leproust S, Levy-Bachelot L, Gourmelen J.

Value Health. 2015 Nov;18(7):A599. doi: 10.1016/j.jval.2015.09.2054. Epub 2015 Oct 20. No abstract available.

15.

The Relationship Between Glucose-Lowering Medications, Adherence, and Outcomes in Patients with Type 2 Diabetes.

Piercy J, Milligan G, Davies MJ, Detournay B, Orozco Beltran D, Chubb B, Bottomley JM, Nicolucci A, Jacob S.

Value Health. 2015 Nov;18(7):A343. doi: 10.1016/j.jval.2015.09.155. Epub 2015 Oct 20. No abstract available.

16.

Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.

Detournay B, Halimi S, Robert J, Deschaseaux C, Dejager S.

Vasc Health Risk Manag. 2015 Jul 17;11:417-25. doi: 10.2147/VHRM.S84507. eCollection 2015.

17.

Impact of socio-economic position on health and quality of care in adults with Type 2 diabetes in France: the Entred 2007 study.

Fosse-Edorh S, Fagot-Campagna A, Detournay B, Bihan H, Eschwege E, Gautier A, Druet C.

Diabet Med. 2015 Nov;32(11):1438-44. doi: 10.1111/dme.12783. Epub 2015 May 8.

PMID:
25884777
18.

Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study.

Darbà J, Kaskens L, Detournay B, Kern W, Nicolucci A, Orozco-Beltrán D, Ramírez de Arellano A.

Clinicoecon Outcomes Res. 2015 Mar 23;7:163-71. doi: 10.2147/CEOR.S78132. eCollection 2015.

19.

[Management and costs of chronic pulmonary obstructive disease in France in 2011].

Laurendeau C, Chouaid C, Roche N, Terrioux P, Gourmelen J, Detournay B.

Rev Mal Respir. 2015 Sep;32(7):682-91. doi: 10.1016/j.rmr.2014.10.731. Epub 2015 Jan 19. French.

20.

Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.

Dervaux B, Baseilhac E, Fagon JY; participants of round table n4 of Giens XXIX : Biot Claire 4 Blachier Corinne 5 Braun Eric 6 Debrou, Biot C, Blachier C, Braun E, Debroucker F, Detournay B, Ferretti C, Granger M, Jouan-Flahault C, Lussier MD, Meyer A, Muller S, Pigeon M, De Sahb R, Sannié T, Sapède C, Vray M.

Therapie. 2014 Jul-Aug;69(4):323-8. doi: 10.2515/therapie/2014048. Epub 2014 Aug 12. English, French.

PMID:
25230355

Supplemental Content

Loading ...
Support Center